Abbott Laboratories $ABT Stock Holdings Decreased by Farmers Trust Co.

Key Points

• Farmers Trust Co. reduced its stake in Abbott Laboratories by 19.3% during Q2, selling 4,552 shares, leaving them with 19,071 shares valued at approximately $2.59 million.
• Institutional investors now own 75.18% of Abbott Laboratories' stock, with several hedge funds making new investments in the company during the first quarter of this year.
• Abbott Laboratories declared a quarterly dividend of $0.59 per share, with an ex-dividend date of October 15th, representing an annualized dividend of $2.36 and a yield of 1.7%.

Farmers Trust Co. lowered its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 19.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 19,071 shares of the healthcare product maker's stock after selling 4,552 shares during the period. Farmers Trust Co.'s holdings in Abbott Laboratories were worth $2,594,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Hughes Financial Services LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $30,000. JCIC Asset Management Inc. bought a new position in Abbott Laboratories in the 1st quarter worth about $32,000. Finally, Vision Financial Markets LLC bought a new position in Abbott Laboratories in the 1st quarter worth about $33,000. Institutional investors own 75.18% of the company's stock.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ABT shares. Wells Fargo & Company decreased their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research report on Friday, July 18th. Leerink Partners started coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price for the company. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their target price for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Morgan Stanley upped their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Evercore ISI upped their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $145.22.

Abbott Laboratories Stock Up 0.6%

ABT stock opened at $136.82 on Tuesday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market cap of $238.13 billion, a price-to-earnings ratio of 17.15, a PEG ratio of 2.58 and a beta of 0.69. The company has a 50 day moving average of $130.56 and a two-hundred day moving average of $131.11.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The company's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.7%. Abbott Laboratories's dividend payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.